Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]

13371 reported adverse events

Drugs of this class: NIRSEVIMAB PALIVIZUMAB

These side effects are most commonly reported by patients taking drugs of the Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] class:

# Side effect Count
0 RESPIRATORY SYNCYTIAL VIRUS INFECTION 1916
1 PYREXIA 1208
2 BRONCHIOLITIS 1131
3 DEATH 957
4 COUGH 835
5 PNEUMONIA 812
6 DYSPNOEA 672
7 VOMITING 568
8 NASOPHARYNGITIS 531
9 BRONCHITIS 394
See all common reactions for Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]

Drugs of the Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 RESPIRATORY SYNCYTIAL VIRUS TEST NEGATIVE 5 0.8333
1 RESPIRATORY SYNCYTIAL VIRUS TEST POSITIVE 289 0.6451
2 RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS 279 0.6284
3 TETRALOGY OF FALLOT REPAIR 4 0.5714
4 ACQUIRED EPIBLEPHARON 2 0.5000
5 PSEUDOCROUP 6 0.4615
6 BRONCHIOLITIS 1131 0.3996
7 RESPIRATORY SYNCYTIAL VIRUS BRONCHITIS 27 0.3971
8 BARTH SYNDROME 3 0.3750
9 RESPIRATORY SYNCYTIAL VIRUS INFECTION 1916 0.3685
See all enriched reactions for Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]